Description
Background:
Cinrebafusp alfa is a bivalent, bispecific fusion protein comprised of an anti-human epidermal growth factor receptor (HER2) monoclonal antibody linked to a CD137-targeting anticalin. Upon administration of cinrebafusp alfa, CD137 clustering is promoted by bridging CD137-positive T cells with HER2-positive tumor cells, leading to the recruitment of tumor antigen-specific cytotoxic T-lymphocytes (CTLs), resulting in potent CTL-mediated lysis of HER2-expressing tumor cells. Currently, cinrebafusp alfa is being studied as a combination therapy for various HER2 tumors.
Intended Use:
For Estimation of Cinrebafusp alfa in human serum and plasma. Krishgen’s range of KRIBIOLISA kits are developed using the high quality raw materials and are thoroughly validated for accuracy and precison. They allow quantification of serum or plasma protein drug levels, and can be used for biosimilar and generics research to understand pharmacokinetic properties of the drug. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us for optimisation.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!